Evaluation of effective neo-adjuvant chemotherapy (FLEP therapy) in the treatment of advanced gastric cancer

Ten patients with non-resectable gastric cancer were subjected to a neo-adjuvant chemotherapy (FLEP therapy), consisting of 4 drugs (leucovorin and 5-FU i.v., CDDP and etoposide i.a.) combination therapy from August 1989 to April 1991. The response rate of this therapy with primary lesions, metastatic lymph-nodes (mainly paraaortic lymph nodes), metastatic liver tumor and peritoneal dissemination were 50, 50, 25 and 33%, respectively. Five cases underwent total gastrectomy. Pathological evaluation of these cases was Grade 1 or 2. Side effects were mainly gastrointestinal disturbances, namely stomatitis, nausea, vomiting and anorexia, along with bone marrow suppression. Performance status of these patients improved to a significant degree by the therapy. This therapy seemed to be effective in controlling paraaortic lymph-node metastasis. The advantage of i.a. delivery was investigated by Tc-MAA scintigraphy. The distribution of Tc-MAA after i.a. injection suggested that i.a. chemotherapy enhanced intraabdominal drug concentration. There is no established treatment for far advanced cases, so this therapy seems to be worth a try.     

多途径综合治疗原发性巨块型肝癌48例疗效分析

作者对４８例不能一期切除的原发性巨块型肝癌进行多途径的综合治疗。在一期探查术中应用肝动脉结扎、碘化油化疗药物（ＭＤＦ）混合液灌注化疗和液态硅胶（ＴＨ）栓塞术；术后行肝动脉、门静脉分期灌注化疗；化疗间期经皮向癌灶内分点注射无水酒精。综合治疗半年复查结果：ＰＲ６６．７％、ＭＲ２２．９％、ＳＤ１０．４％。复查后依据病情施行Ⅱ期手术切除２３例，占本组病例的４７．９％（２３／４８）。本组病例随访结果：６、８、１０个月、１、３、５年生存率分别为９３．８％、８７．５％、７９．２％、７５．０％、５６．１％、２５．９％。结果显示，多途径综合治疗疗效显著。     

原发性肝癌的三级根治切除标准

目的阐述原发性肝癌三级根治切除标准的内容并评价其临床意义.方法根据根治标准的完善程度将肝癌根治切除标准分为3级.Ⅰ级标准完整切除肉眼所见肿瘤,切缘无残癌.Ⅱ级标准在Ⅰ级标准基础上增加4项条件(1)肿瘤数目不超过2个;(2)无门脉主干及一级分支、总肝管及一级分支、肝静脉主干及下腔静脉癌栓;(3)无肝门淋巴结转移;(4)无肝外转移.Ⅲ级标准在Ⅱ级标准基础上增加术后随访结果阴性条件,即术后2个月内AFP降至正常(术前AFP阳性者)和影像学检查未见肿瘤残存.回顾性分析354例肝癌患者行肝切除治疗的临床资料,按3级标准的根治与否分为6组Ⅰ级标准根治组,Ⅰ级标准姑息组;Ⅱ级标准根治组,Ⅱ级标准姑息组;Ⅲ级标准根治组,Ⅲ级标准姑息组.寿命表法计算各组生存率,并加以比较.结果原发性肝癌各根治切除组生存率均高于相应姑息组(P<0.01).随着采用根治标准级别的升高,其切除后生存率也逐级提高,Ⅰ级、Ⅱ级和Ⅲ级标准根治组5年生存率分别为43.2%、51.2%和64.4%,各组生存率差异有显著性(P<0.01).结论原发性肝癌手术切除可以采用分级根治标准判定手术根治性.所应用的根治标准越严格,其获得的疗效越好.按较高级别肝癌根治切除标准选择病例、实施手术和加强随访,将提高肝癌切除手术疗效.     

“Three-Grade Criteria” of Radical Resection for Primary Liver Cancer

OBJECTIVE The present study was designed to develop the “Three- Grade Criteria” for radical resection of primary liver cancer （PLC） and to evaluate its clinical significance. METHODS Criteria for radical resection of PLC were summed up to 3 grades based on criterion development. Grade Ⅰ： complete removal of all gross tumors with no residual tumor at the excision margin. Grade Ⅱ： on the basis of Grade Ⅰ, additional 4 requirements were added： （1） the tumor was not more than two in number; （2） no tumor thrombi in the main trunks or the primary branches of the portal vein, the common hepatic duct or its primary branches, the hepatic veins or the inferior vena cava; （3）no hilar lymph nodes metastases; （4）no extrahepatic metastases. Grade Ⅲ ： in addition to the above criteria, negative postoperative follow-up result including AFP dropping to a normal level （with positive AFP before surgery） within 2 months after operation, and no residual tumor upon diagnostic imaging.The clinical data from 354 patients with PLC who underwent hepatectomy were reviewed retrospectively. Based on the “Three-Grade Criteria” these patients were divided into 6 groups： Grade Ⅰ radical group, Grade Ⅰ palliative group, Grade Ⅱ radical group, Grade Ⅱ palliative group, Grade Ⅲ radical group, Grade Ⅲ palliative group. The survival rate of each group was calculated by the life-table method and the rates compared among the groups. RESULTS The survival rate of patients receiving radical treatment was better than those receiving palliative treatment （P〈0.01）. Survival improved as more criteria were applied. The 5-year survival rate of the patients in Grade Ⅰ, Ⅱ and Ⅲ who underwent radical resection was 43.2%, 51.2% and 64.4%, respectively （P〈0.01）. CONCLUSION The “Three-Grade Criteria” may be applied for judging the curability of resection therapy for PLC. The stricter the criterion used, the better the survival would be. Adopting high-grade criteria to select cases and guide operations and strengthening postoperative follow-up would improve the results of hepatectomy for PLC.     

A simplified surgical technical procedure for intra-arterial chemotherapy in secondary liver cancer. Experience in 50 patients

The purpose of this study was to prove that only one intra-arterial catheter for hepatic chemotherapy can perfuse the whole liver in all anatomic cases, including cases with aberrant or accessory hepatic arteries. The ligations of various hepatic arteries induce the immediate aperture of intra hepatic arterial shunts and a total revascularization of the whole liver by the only remaining hepatic artery. Based on the experience from 50 consecutive cases of surgical implantation of intra-arterial catheters for local chemotherapy, the simplified technique is analysed principally as a function of anatomical variations of the hepatic artery. The usual procedure (catheter implanted into the gastro-duodenal artery) was performed in 58% of the cases, while in 28% of the cases this was possible only after section of a right and/or a left aberrant or accessory hepatic artery. Unusual implantations were necessary in 14% of the cases to ensure complete perfusion of liver. The evaluation was based on three criteria: intra-operative perfusion of fluorescein, post-operative scan with 99mTc macro-aggregated albumin and objective clinical responses after intra-arterial chemotherapy. The perfusion of the whole liver was good in all cases except one. Unusual procedures gave the same clinical objective responses after intra-arterial chemotherapy (61%) as usual procedures (48%) (chi-square: P = 0.40).     

Characterization of extrahepatic distribution of Tc-99m macroaggregated albumin in hepatic perfusion imaging studies prior to yttrium-90 microsphere therapy

Tc-99m macroaggregated albumin (MAA) hepatic perfusion study and hepatic angiography are routinely performed prior to yttrium-90 (Y-90) microsphere therapy for patients with hepatocellular carcinoma (HCC) or metastatic cancers to the liver. The purpose of this study was to examine the incidence of altered Tc-99m MAA distribution in these patients and to identify factors that are associated with these changes. A total of 176 Tc-99m MAA hepatic perfusion studies in 159 patients performed in preparation for Y-90 microsphere therapy were retrospectively reviewed. Abnormal findings were identified and correlated with diagnosis, infusion site, tumor volume, and tumor uptake by using bivariate statistical analysis. Abnormal Tc-99m MAA distribution on the hepatic perfusion imaging studies include excessive hepatopulmonary shunting with an elevated shunting fraction (>10%; n=23, 13%) and abnormal intra-abdominal visceral deposition in the GI tract, pancreas, spleen, and umbilical vein (n=19; 11%). Patients with a diagnosis of HCC showed higher incidence of abnormal hepatopulmonary shunting compared with other types of tumors (p<0.05). The incidence of abnormal intra-abdominal visceral deposition is higher with infusion into the left hepatic artery or proper hepatic artery/common hepatic artery compared with infusion into right hepatic artery (p<0.001). In 9 of 12 cases with abnormal deposition in the stomach, duodenum, or pancreas, the cause was identified upon reviewing angiography retrospectively and was subsequently corrected. In conclusion, the hepatic perfusion imaging study is an important imaging modality in preparation and guidance of Y-90 microsphere treatment.     

Regional Chemotherapy in Liver Metastases of Colorectal Carcinoma: Monitoring with Arterial Computed Tomography

Continuous chemotherapy was administered to 82 patients through the hepatic artery via Infusaid pumps. In order to obtain a primary status and to evaluate the success of therapy, the perfusion patterns of the liver and of the existing tumor masses in the liver were estimated by conducting arterial angiocomputed tomographies (AACTs) immediately after pump implantation of every 3 months thereafter. In 70% of the patients, findings showed both liver lobes to be homogeneously perfused, 24% demonstrated distinct inhomogeneities. The response of the latter cases should depend primarily on the efficacy of the administered cytostatic agent. Six percent of the patients showed selective perfusion of either the left or right hepatic lobe. In these cases, only me perfused liver regions exhibited stable disease or regression of the metastases, whereas the metastases of the nonperfused regions progressed. At 3-month follow-up, the majority of the patients (50-57%) showed homogeneous hepatic perfusion. Inhomogeneities were found in 26-36% of the patients, 12 patients demonstrated incomplete perfusion. There was no association between the perfusion patterns of the metastases or of the prechemotherapeutic liver involvement and the response of the metastases to regional chemotherapy. In regional chemotherapy, liver perfusion should be controlled both intraoperatively or directly postoperatively and during therapy.     

Effect of hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer

We performed hepatic arterial infusion (HAI) chemotherapy for 4 patients with advanced gastric cancer who had undergone curative resection except for liver metastasis. The main antineoplastic drugs were 5-fluorouracil (5-FU), mitomycin C (MMC) and cisplatin (CDDP). A catheter was inserted into the hepatic artery by interventional radiological techniques in 3 patients and operatively in 1 patient. The response rate for 4 patients was 75% (CR2, PR1, PD1). The adverse events were Grade 3/4 nausea and/or vomiting in 2 cases. The HAI chemotherapy was effective and useful for patients with advanced gastric cancer who had no unresectable lesions except for liver metastasis.     

Magnetic resonance imaging of cranial radiation lesions

Fifty-six patients who previously received therapeutic cranial irradiation (CRT) were imaged by a 1.5 Magnetic Resonance (MR) System 0.1-11 years following CRT. Abnormal MR findings within the treatment volume unrelated to tumor, prior to surgery, or coexisting conditions were reviewed for an association with CRT. Twenty-four patients had MR abnormalities considered to be attributable to CRT. These were scored as mild (Grade I) in 6, moderate (Grade II) in 9, and severe (Grade III) in 9. Eight of these 24 patients with CRT findings on MR had CT abnormalities that correlated with the MR. Six lesions seen on computed tomography (CT) were Grade III abnormalities; all were judged as being visualized better by MR. Eight patients had significant neurologic dysfunction attributable to their CRT lesions, and 7 of these had Grade III lesions. Whereas the clinical significance of mild or moderate CRT effects seen on MR is uncertain, Grade III (severe) MR lesions correlate well with important clinical findings.     

Results of liver angiography and perfusion scintigraphy do not correlate with response to hepatic artery infusion chemotherapy

Liver angiography and liver perfusion scintigraphy with Tc-99m-labeled macroaggregated albumin (MAA) were performed in 36 patients with liver metastases from colorectal cancer prior to continuous 5-fluorouracil hepatic artery infusion (HAI) hemotherapy. Of the 26 patients showing metastases on arteriogram, five revealed increased tumor vascularisation, five had normal vascularisation, and 16 showed decreased vascularisation of the metastases relative to liver. In liver perfusion scintigraphy, 15 of the 36 patients showed increased perfusion of the metastases, four had normal perfusion, and 17 had decreased tumor perfusion. The observed differences in survival in the different groups were not statistically significant: patients survived 15 months in the group with increased tumor vascularisation, 8 months for normal vascularisation, and 14 months for decreased tumor vascularisation; survival was 28 months for the group of increased, and 13 and 14 months for the normal and decreased tumor perfusion groups respectively. Also, response rates with 80%, 40%, and 75% responders in the group of increased, normal, and decreased tumor vascularisation, respectively, and 80%, 50%, and 59% responders in the group of increased, normal, and decreased perfusion, respectively, were not significantly different. These results indicate that there is no possibility to discriminate potential responders from nonresponders by results of liver angiography or perfusion scintigraphy.     

Repetitive chemo-embolization with degradable starch microspheres (DSM) to each left and replaced right hepatic artery in a patient with multiple liver metastases of colon cancer

In a patient with a right hepatic artery arising from the superior mesenteric artery bearing multiple liver metastases from colon cancer, hepatic arterial chemo-embolization was performed in combination with degradable starch microspheres (DSM) administered independently to the left and replaced right hepatic artery via a percutaneal approach. As the first line chemotherapy from hepatic artery with DSM 300 mg, 5-FU 500 mg and MMC 10 mg resulted in PD. DSM 300 mg, epirubicin (EPI) 50 mg, MMC 4 mg was administered with the RHA:LHA ratio of 3:1 as a second line. Four weeks later it was evaluated as NC by angiography and by tumor-marker dropped extremely. The same regimen was repeated every four weeks, and the NC status remained for 20 weeks in total. Each time, the left and replaced right hepatic artery got perfect re-perfusion and DSM enabled an effective whole liver distribution of anti-cancer drugs and repetitive administrations of them. This regimen could be an alternative choice for patients with a replaced right hepatic artery who have liver metastasis of colon cancer.     

Uptake of 5-fluorouracil during isolated perfusion of the canine liver

This study describes a technique of hepatic isolated perfusion in dogs. The uptake of 14 C-Iabeled 5 fluorouracil (5-FU) by the normal canine liver was fourfold greater when isolated perfusion was used than when peripheral intravenous administration or hepatic artery infusion were applied. Systemic leakage of 5-FU was small during, and even following, hepatic isolated perfusion. This technique, which maximizes chemotherapy delivery to the liver while minimizing systemic toxicity, may be useful in the treatment of primary and metastatic hepatic malignancies.     

Styrene maleic acid neocarzinostatin-transcatheter embolization for hepatocellular carcinoma--third report

To evaluate the effect of styrene maleic neocarzinostatin-transcatheter arterial embolization (SMANCS-TAE), 40 patients with unresectable hepatocellular carcinoma (HCC) of hypervascular radiological feature, associated with liver cirrhosis (LC), 18 in clinical stage 2 and 20 in stage 3, were treated by SMANCS-TAE. SMANCS with Lipiodol and then gelatin sponge particles were injected into the artery branch supplying HCC using selective catheterization, and its effect was evaluated by computed tomography (CT) Grade. In patients with Grade III or less (Lipiodol accumulation < 99% in the entire tumor) after the first course of therapy, SMANCS-TAE or arterial injection of SMANCS-Lipiodol was performed once or twice more. Consequently, 32 of 40 patients (80%) obtained Grade IV (100% Lipiodol accumulation in the entire tumor) after from once to thrice (median, 1.6 courses). Grade IV was maintained in 26 of 32 patients, and non-recurrence was found 16 of 40 (40%) at the primary tumor to the time at last of follow up. Severe side effects were not noted except in 10 cases with narrowness of hepatic artery and cases of 2 biloma in patients undergoing therapy two or more times. The 1-, 2-, 3-, and 5-year survival rate was 85, 64, 35, and 26%, respectively. No significant difference was noted in the survival rate between clinical stage 2 and 3 liver cirrhosis (LC). But the survival rate of patients who continued to exhibit Grade IV at the primary tumor was significantly better than in those exhibiting Grade III or less (96, 68, 56, and 43% vs 64, 29, 0, and 0%, respectively; p < 0.01). In conclusion, the HCC patients, even those with decompensated LC, who obtained and maintained Grade IV after SMANCS-TAE could reduce the courses of treatment without severe side effects and survived longer. SMANCS-TAE might be useful for the good quality of life of HCC patients.     

A case of hepatic metastasis of gastric cancer responding to TS-1, administered for two consecutive weeks and one week rest

We have treated a case of hepatic metastasis of gastric cancer that has responded well to TS-1. The patient was a 68-year-old male, who underwent distal gastrectomy for gastric cancer. After surgery 5'-deoxy-5-fluorouridine (5'-DFUR) 800 mg/day was administered orally for two months. Grade 4 diarrhea appeared, so administration of 5'-DFUR was discontinued. Afterward the patient was followed with no chemotherapy. Liver metastasis (S6, 3 cm in diameter) was found at twelve months after surgery. 5'-DFUR (800 mg/day) was administered orally everyday. Grade 3 diarrhea appeared and metastasis showed NC after four weeks. 5'-DFUR administration was discontinued. Seventeen days later TS-1 (80 mg/day) was administered orally everyday for 2 weeks, followed by 1 week rest, as one course. Two courses of TS-1 administration resulted in a marked reduction of the liver metastasis, for a PR (75% reduction). After 3 courses, the liver metastasis showed CR. The patient is alive without recurrence after 12 courses. This TS-1 administration regimen was effective and tolerable for a patient with liver metastasis from gastric cancer.     

免VX2肝癌TACE前后MRDWI与病理对照研究

目的:本研究利用兔VX2肝癌模型,探讨肝癌化疗栓塞后MR弥散加权成像及病理表现,为肝癌化疗栓塞后的疗效评价提供理论基础.方法:新西兰大白兔15只,制成VX2肿瘤模型.随机分为3组.分别为TACE术前、术后三天、术后一周组.种植3周,进行肝动脉化疗栓塞.采用sendinger穿刺技术,将3F微导管超选入肿瘤供血动脉,注射碘油、MMC(1mg)及表阿霉素(1mg)混合物0.5～1mL.至碘油沉积良好、肿瘤血管消失停止.各组在TACE术前、术后三天、术后一周分别进行MR弥散加权成像.DWI采用单次激发平面回波成像序列,弥散因子b值取0s/mm~2和300s/mm~2,TR 6000ms,TE 49ms,FOV 150mm,层厚3mm,层间距0mm,矩阵112×112,重建矩阵256×256,翻转角90°,扫描时间2分36秒,NSA为6次.成像之后动物处死,切取肝脏肿瘤组织块,进行HE染色、病理观察.结果:化疗栓塞前,MR DWI可见高信号肿瘤灶.光镜下肿瘤组织细胞体积增大,胞浆丰富,淡红染色,核肥大,核分裂像多见,可见少量坏死,周边区和中央区未见明显区别.栓塞后3天,肝左叶肿瘤DWI上为高信号区,出现斑片状低信号区.光镜下出现大量核碎裂、核溶解,肿瘤坏死较多.栓塞后1周,在DWI上低信号的坏死区增加.光镜下核碎裂、核溶解、肿瘤坏死增多.结论:MR弥散加权成像与病理表现一致,较好地体现了肝癌化疗栓塞后的转归.     

Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement

Variation in response rates to chemotherapy and survival in patients with hepatic metastases from colorectal carcinoma may be due to patient selection factors. The prognostic importance of 13 factors were analyzed in 112 patients with only hepatic metastases, who were eligible for hepatic artery infusional chemotherapy. When individually analyzed, six factors were found to significantly (less than 0.001) affect survival: the percentage of tumor involvement of the liver, assessed medically or surgically; initial serum albumin and lactic dehydrogenase; initial Karnofsky performance status; and weight loss. Patients with less than or equal to 30% liver involvement had a median survival of 24 months versus 10 months if they had greater than 30% involvement. There was a highly significant agreement between medical and surgical assessment of liver involvement (P = 0.0001). When the variables affecting survival were studied together by multivariable analyses, the most important factor was the medical assessment of liver involvement accomplished by evaluation of radionuclide liver scan and CTT scans. The next two most important factors in the model were the ability of the patient to obtain a tumor response and the presence or absence of weight loss. Only one factor helped predict response to chemotherapy, the type of perfusion seen on a 99Technetium-macroaggregated albumin (MAA) arterial flow scan. Forty-five percent of patients with good perfusion had a partial response while 13% of patients with poor perfusion had a tumor response (P = 0.006). We recommend that future studies, dealing with patients who have hepatic metastases from colorectal carcinoma and are eligible for hepatic arterial infusion, document and stratify for the following factors: the percentage of liver involvement, the presence or absence of weight loss, and the type of perfusion seen on MAA scans.     

Management of malignant ovarian immature teratoma. Role of adriamycin

Sixteen consecutive patients with pure ovarian immature teratoma have been treated at The Norwegian Radium Hospital between 1975 and 1987. The median age was 22 years. Thirteen patients had International Federation of Gynecology and Obstetrics (FIGO) Stage I disease and three had Stage III disease. None of the patients with Stage I disease had bilateral disease. In nine patients at least one ovary was conserved. Four cases were Grade 1, seven cases Grade 2, and five cases Grade 3. Adjuvant treatment consisted mainly of Adriamycin (Adria Laboratories, Columbus, OH). The chemotherapy regimen appeared to be highly effective because all patients are alive without evidence of disease (median follow-up, 85 months). No severe toxicity was observed. In patients without residual tumor after primary surgery, the authors prefer the adjuvant treatment with Adriamycin because this treatment has a lower toxicity and is as effective as combination chemotherapy (vincristine, dactinomycin, and cyclophosphamide or cisplatin, vinblastine and bleomycin). Some comments on initial surgery and second-look surgery are also given.     

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv

Combinatorial variation of CDR3 of V(H) and V(L), followed by phage display, was used to select affinity mutants of the parental anti-epidermal growth factor receptor-vIII (EGFRvIII) scFv MR1. One mutant, MR1-1(scFv), had increased specific binding affinity for EGFRvIII. It was produced and radiolabeled, and its biodistribution was evaluated in human glioma-bearing athymic mice. MR1-1 targeted the same EGFRvIII epitope as MR1 with an approximately 15-fold higher affinity (K(d) = 1.5 x 10(-9) M) measured by surface resonance analysis. Labeling with (131)I or (125)I was performed, and the immunoreactive fraction of the labeled MR1-1(scFv) was 50% to 55%. After incubation at 37 degrees C for 4 days, the binding affinity was maintained at 60% of initial levels. The specificity of MR1-1 for EGFRvIII was demonstrated in vitro by flow cytometry and incubation of FITC-labeled scFv with the EGFRvIII-expressing U87MG. DeltaEGFR cell line or with the EGFRvIII-negative U87MG cell line in the presence or absence of competing unlabeled MR1-1(scFv). We also investigated the internalization and processing of MR1-1 compared with MR1; MR1-1 exhibited levels of both cell surface retention and internalization up to 5 times higher than those by MR1. In biodistribution studies performed in athymic mice bearing s.c. U87MG. DeltaEGFR tumor xenografts, animals received paired-label intratumoral infusions of (131)I-labeled MR1-1(scFv) and (125)I-labeled MR1(scFv). Our results showed an up to 244% +/- 77% increase in tumor uptake for MR1-1 compared with that for MR1. The improved tumor retention of MR1-1(scFv) combined with its rapid clearance from normal tissues also resulted in sustained higher tumor:normal organ ratios. These results suggest that the improved affinity of MR1-1 can significantly impact in vivo glioma-specific targeting and immunotherapy.     

A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy

A 56-year-old man who underwent distal gastrectomy at another hospital was admitted to our hospital because of advanced gastric cancer with synchronous liver metastasis. As we considered that the metastatic liver tumor was unresectable one, an intra-arterial catheter was inserted and weekly chemotherapy including methotrexate (MTX) (intra-venous) and 5-fluorouracil (5-FU) (intra-arterial) was started. The metastatic liver tumor was gradually reduced and resulted in partial response (PR) after 12 courses. Eight months later, the size of the metastatic liver tumor increased and lung metastasis occurred, so we started a new regimen of chemotherapy using CPT-11 (intra-venous) and CDDP (intra-arterial). After 4 courses of this regimen, we gained PR both in the metastatic liver and lung tumor. This case indicates that the combination therapy of systemic and hepatic arterial infusion chemotherapy is a treatment option in cases of advanced gastric cancer with liver metastasis.     

肝动脉泵内化疗治疗晚期肝癌的临床研究

目的：观察肝动脉泵内化疗对晚期肝癌的疗效。方法：泵内予以ＦＤ和ＦＭ方案交替小剂量化疗（每周一次,６个月为一疗程）治疗１２例晚期肝癌患者。结果：ＣＲ４例,ＰＲ４例,ＮＣ２例,ＰＤ２例。有效率为６６．７％（８／１２）。３年及５年生存率分别为３３．３％和１６．７％。结论：泵内长期小剂量化疗可以提高晚期肝癌的生存率。